SCHEMBL978655

SCHEMBL978655

COC(=O)c1ccc2cc(-c3ccccc3)oc2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 5/20 0.68
HDAC3 O15379 1/20 0.57
HDAC1 Q13547 1/20 0.57
HDAC2 Q92769 1/20 0.57
HDAC8 Q9BY41 1/20 0.57
TNKS O95271 1/20 0.56
PSMB8 P28062 1/20 0.48
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NFKB1 P19838 1/20 0.47
NPY1R P25929 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
TSHR P16473 1/20 0.46
HPGD P15428 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18838242 0.89 HDAC6 (0.55) HDAC6HDAC3HDAC1HDAC2HDAC8
SCHEMBL980266 0.89 TNKS (0.56) HDAC6TNKSKDM4EALDH1A1NPC1
SCHEMBL5031445 0.86 HDAC6 (0.58) HDAC6HDAC3HDAC1HDAC2HDAC8
SCHEMBL21860495 0.86 HDAC6 (0.52) HDAC6HDAC3HDAC1HDAC2HDAC8
SCHEMBL5031505 0.85 HDAC6 (0.78) HDAC6HDAC3HDAC1HDAC2HDAC8
SCHEMBL3981377 0.84 TNKS (0.69) HDAC6HDAC2TNKSKDM4EALDH1A1
SCHEMBL9133186 0.84 HDAC6 (0.50) HDAC6HDAC3HDAC1HDAC2HDAC8
SCHEMBL977056 0.83 HDAC6 (0.73) HDAC6HDAC3HDAC1HDAC2HDAC8
SCHEMBL19029316 0.81 HDAC6 (1.00) HDAC6HDAC3HDAC1HDAC2HDAC8
SCHEMBL6485304 0.81 TNKS (0.57) HDAC6TNKSKDM4EALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282742-A1 BENZOFURAN DERIVATIVES FOR TARGETING AUTOPHAGY Automera PTE. LTD (SG) 2025-09-11 US disclosed
EP-3621957-B1 FUSED STILBENE DERIVATIVES AS SOLAR CELL DYES AMBIENT PHOTONICS INC (US) 2023-08-23 EP disclosed
US-20230154691-A1 Stilbene and Fused Stilbene Derivatives as Solar Cell Dyes Ambient Photonics, Inc. (US) 2023-05-18 US disclosed
US-20110021540-A1 Bis-(Sulfonylamino) Derivatives in Therapy 066 ASTRAZENECA AB (SE) 2011-01-27 US disclosed
EP-2217566-A1 BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 AstraZeneca AB (SE) 2010-08-18 EP disclosed
US-20090281138-A1 Bis-(Sulfonylamino) Derivatives in Therapy 066 ASTRAZENECA AB (SE) 2009-11-12 US disclosed
WO-2009064250-A1 BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 ASTRAZENECA AB (SE) 2009-05-22 WO disclosed
WO-2009064251-A1 BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 ASTRAZENECA AB (SE) 2009-05-22 WO disclosed
US-20090131468-A1 Bis-(Sulfonylamino) Derivatives in Therapy 065 ASTRAZENECA AB (SE) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131468-A1 Bis-(Sulfonylamino) Derivatives in Therapy 065 PTGER1, CYP3A5, SULT1E1 HDAC6 3409/4885HDAC3 1983/4885HDAC1 2889/4885
US-20090281138-A1 Bis-(Sulfonylamino) Derivatives in Therapy 066 CYP2D6, PTGER1, CYP2B6 HDAC6 3831/4885HDAC3 2511/4885HDAC1 2735/4885
US-20250282742-A1 BENZOFURAN DERIVATIVES FOR TARGETING AUTOPHAGY SQSTM1, BECN1, TFEB HDAC6 39/4885HDAC3 114/4885HDAC1 244/4885
US-20230154691-A1 Stilbene and Fused Stilbene Derivatives as Solar Cell Dyes FDFT1, SUN2, CDC73 HDAC6 4514/4885HDAC3 4278/4885HDAC1 2501/4885
US-20110021540-A1 Bis-(Sulfonylamino) Derivatives in Therapy 066 CYP2D6, PTGER1, CYP2B6 HDAC6 3831/4885HDAC3 2511/4885HDAC1 2735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.